Diagnostic screening of MODY2/GCK mutations in the Norwegian MODY Registry
Jørn V Sagen
Section for Endocrinology, Institute of Medicine, University of Bergen, Bergen, Norway
Section for Pediatrics, Department of Clinical Medicine, University of Bergen, Bergen, Norway
Search for more papers by this authorLise Bjørkhaug
Section for Pediatrics, Department of Clinical Medicine, University of Bergen, Bergen, Norway
Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway
Search for more papers by this authorJanne Molnes
Section for Pediatrics, Department of Clinical Medicine, University of Bergen, Bergen, Norway
Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway
Search for more papers by this authorHelge Ræder
Section for Pediatrics, Department of Clinical Medicine, University of Bergen, Bergen, Norway
Department of Pediatrics, Haukeland University Hospital, Bergen, Norway
Search for more papers by this authorLouise Grevle
Section for Pediatrics, Department of Clinical Medicine, University of Bergen, Bergen, Norway
Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway
Search for more papers by this authorOddmund Søvik
Section for Pediatrics, Department of Clinical Medicine, University of Bergen, Bergen, Norway
Search for more papers by this authorAnders Molven
Section for Pathology, The Gade Institute, University of Bergen, Bergen, Norway
Department of Pathology, Haukeland University Hospital, Bergen, Norway
Search for more papers by this authorCorresponding Author
Pål R Njølstad
Section for Pediatrics, Department of Clinical Medicine, University of Bergen, Bergen, Norway
Department of Pediatrics, Haukeland University Hospital, Bergen, Norway
Pål R Njølstad, MD, PhDSection for PediatricsDepartment of Clinical MedicineUniversity of BergenN-5021 BergenNorway.Tel: +47 55975153;fax: +47 55975147;e-mail: [email protected]Search for more papers by this authorJørn V Sagen
Section for Endocrinology, Institute of Medicine, University of Bergen, Bergen, Norway
Section for Pediatrics, Department of Clinical Medicine, University of Bergen, Bergen, Norway
Search for more papers by this authorLise Bjørkhaug
Section for Pediatrics, Department of Clinical Medicine, University of Bergen, Bergen, Norway
Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway
Search for more papers by this authorJanne Molnes
Section for Pediatrics, Department of Clinical Medicine, University of Bergen, Bergen, Norway
Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway
Search for more papers by this authorHelge Ræder
Section for Pediatrics, Department of Clinical Medicine, University of Bergen, Bergen, Norway
Department of Pediatrics, Haukeland University Hospital, Bergen, Norway
Search for more papers by this authorLouise Grevle
Section for Pediatrics, Department of Clinical Medicine, University of Bergen, Bergen, Norway
Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway
Search for more papers by this authorOddmund Søvik
Section for Pediatrics, Department of Clinical Medicine, University of Bergen, Bergen, Norway
Search for more papers by this authorAnders Molven
Section for Pathology, The Gade Institute, University of Bergen, Bergen, Norway
Department of Pathology, Haukeland University Hospital, Bergen, Norway
Search for more papers by this authorCorresponding Author
Pål R Njølstad
Section for Pediatrics, Department of Clinical Medicine, University of Bergen, Bergen, Norway
Department of Pediatrics, Haukeland University Hospital, Bergen, Norway
Pål R Njølstad, MD, PhDSection for PediatricsDepartment of Clinical MedicineUniversity of BergenN-5021 BergenNorway.Tel: +47 55975153;fax: +47 55975147;e-mail: [email protected]Search for more papers by this authorAbstract
Background: Maturity-onset diabetes of the young, type 2 (MODY2) is caused by mutations in the glucokinase gene (GCK). The aim of our study was to determine the prevalence of GCK mutations in the Norwegian MODY Registry and to delineate the clinical phenotype of identified GCK mutation carriers.
Methods: We screened 122 probands referred to the MODY Registry for mutations in GCK and studied extended families with MODY2.
Results: We found 2 novel (S76Y and N231S) and 13 previously reported (V62A, G72R, L146R, R191W, A208T, M210K, Y215X, M235T, R275C, E339G, R377C, S453L, and IVS5+1G>C) GCK mutations in 23 probands and in their 33 family members. The prevalence of MODY2 was 12% in the Norwegian MODY Registry. The subjects with GCK mutations had features of mild diabetes. Yet, 15 of 56 MODY2 subjects were treated with oral drugs or insulin. Three subjects had retinopathy and one had macrovascular disease. Also, a limited number of cases had elevated fasting serum triglyceride values. Moreover, two GCK mutation carriers were diagnosed with type 1 diabetes.
Conclusions: According to our diagnostic screening of GCK in the MODY Registry, MODY2 is less prevalent than MODY3 in Norway but is likely to be underreported. Recognizing MODY2 in diabetic patients is important in order to prevent overtreatment. Finally, our study demonstrates the co-occurrence of MODY2 in families with type 1 or type 2 diabetes.
References
- 1 Froguel P, Zouali H, Vionnet N et al. Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus. N Engl J Med 1993: 328: 697–702.
- 2 Matschinsky FM. Regulation of pancreatic beta-cell glucokinase: from basics to therapeutics. Diabetes 2002: 51 (Suppl. 3): S394–S404.
- 3 Gloyn AL. Glucokinase (GCK) mutations in hyper- and hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy. Hum Mutat 2003: 22: 353–362.
- 4 Njølstad PR, Søvik O, Cuesta-Munoz A et al. Neonatal diabetes mellitus due to complete glucokinase deficiency. N Engl J Med 2001: 344: 1588–1592.
- 5 Njølstad PR, Sagen JV, Bjørkhaug L et al. Permanent neonatal diabetes caused by glucokinase deficiency: inborn error of the glucose-insulin signaling pathway. Diabetes 2003: 52: 2854–2860.
- 6 Porter JR, Shaw NJ, Barrett TG, Hattersley AT, Ellard S, Gloyn AL. Permanent neonatal diabetes in an Asian infant. J Pediatr 2005: 146: 131–133.
- 7 Glaser B, Kesavan P, Heyman M et al. Familial hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med 1998: 338: 226–230.
- 8 Christesen HB, Jacobsen BB, Odili S et al. The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy. Diabetes 2002: 51: 1240–1246.
- 9 Gloyn AL, Noordam K, Willemsen MA et al. Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations. Diabetes 2003: 52: 2433–2440.
- 10 Cuesta-Munoz AL, Huopio H, Otonkoski T et al. Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation. Diabetes 2004: 53: 2164–2168.
- 11 Ledermann HM. Is maturity onset diabetes at young age (MODY) more common in Europe than previously assumed? Lancet 1995: 345: 648.
- 12 Velho G, Blanche H, Vaxillaire M et al. Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families. Diabetologia 1997: 40: 217–224.
- 13 Chevre JC, Hani EH, Boutin P et al. Mutation screening in 18 Caucasian families suggest the existence of other MODY genes. Diabetologia 1998: 41: 1017–1023.
- 14 Massa O, Meschi F, Cuesta-Munoz A et al. High prevalence of glucokinase mutations in Italian children with MODY. Influence on glucose tolerance, first-phase insulin response, insulin sensitivity and BMI. Diabetes Study Group of the Italian Society of Paediatric Endocrinology and Diabetes (SIEDP). Diabetologia 2001: 44: 898–905.
- 15 Lindner TH, Cockburn BN, Bell GI. Molecular genetics of MODY in Germany. Diabetologia 1999: 42: 121–123.
- 16 Pearson ER, Velho G, Clark P et al. beta-cell genes and diabetes: quantitative and qualitative differences in the pathophysiology of hepatic nuclear factor-1alpha and glucokinase mutations. Diabetes 2001: 50 (Suppl. 1): S101–S107.
- 17 Lehto M, Wipemo C, Ivarsson SA et al. High frequency of mutations in MODY and mitochondrial genes in Scandinavian patients with familial early-onset diabetes. Diabetologia 1999: 42: 1131–1137.
- 18 Costa A, Bescos M, Velho G et al. Genetic and clinical characterisation of maturity-onset diabetes of the young in Spanish families. Eur J Endocrinol 2000: 142: 380–386.
- 19 Barrio R, Bellanne-Chantelot C, Moreno JC et al. Nine novel mutations in maturity-onset diabetes of the young (MODY) candidate genes in 22 Spanish families. J Clin Endocrinol Metab 2002: 87: 2532–2539.
- 20 Stride A, Vaxillaire M, Tuomi T et al. The genetic abnormality in the beta cell determines the response to an oral glucose load. Diabetologia 2002: 45: 427–435.
- 21 Prisco F, Iafusco D, Franzese A, Sulli N, Barbetti F. MODY 2 presenting as neonatal hyperglycaemia: a need to reshape the definition of ‘neonatal diabetes’? Diabetologia 2000: 43: 1331–1332.
- 22 Page RC, Hattersley AT, Levy JC et al. Clinical characteristics of subjects with a missense mutation in glucokinase. Diabet Med 1995: 12: 209–217.
- 23 Ellard S, Beards F, Allen LI et al. A high prevalence of glucokinase mutations in gestational diabetic subjects selected by clinical criteria. Diabetologia 2000: 43: 250–253.
- 24 Kousta E, Ellard S, Allen LI et al. Glucokinase mutations in a phenotypically selected multiethnic group of women with a history of gestational diabetes. Diabet Med 2001: 18: 683–684.
- 25 Bjørkhaug L, Sagen JV, Thorsby P, Søvik O, Molven A, Njølstad PR. Hepatocyte nuclear factor-1α gene mutations and diabetes in Norway. J Clin Endocrinol Metab 2003: 88: 920–931.
- 26 Sagen JV, Bostad L, Njølstad PR, Søvik O. Enlarged nephrons and severe nondiabetic nephropathy in hepatocyte nuclear factor-1β (HNF-1β) mutation carriers. Kidney Int 2003: 64: 793–800.
- 27 Ræder H, Johansson S, Holm PI et al. Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction. Nat Genet 2006: 38: 54–62.
- 28 Ræder H, Bjørkhaug L, Johansson S et al. A hepatocyte nuclear factor-4α gene (HNF4A) P2 promoter haplotype linked with late-onset diabetes: studies of HNF4A variants in the Norwegian MODY Registry. Diabetes 2006: 55: 1899–1903.
- 29 Gloyn AL, Pearson ER, Antcliff JF et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004: 350: 1838–1849.
- 30 Sagen JV, Ræder H, Hathout E et al. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes 2004: 53: 2713–2718.
- 31 Njølstad PR, Cockburn BN, Bell GI, Søvik O. A missense mutation, Val62Ala, in the glucokinase gene in a Norwegian family with maturity-onset diabetes of the young. Acta Paediatr 1998: 87: 853–856.
- 32
Njølstad PR,
Søvik O,
Matschinsky FM,
Bell GI.
Permanent neonatal diabetes mellitus due to glucokinase deficiency. In: FM Matschinsky,
MA Magnuson, eds. Glucokinase and Glycemic Disease. From Basics to Novel Therapeutics. Basel: Karger, 2004: 65–74.
10.1159/000079007 Google Scholar
- 33
Gloyn AL,
Odili S,
Buettger C et al. Glucokinase and the regulation of blood glucose. In: FM Matschinsky,
MA Magnuson, eds. Glucokinase and Glycemic Disease. From Basics to Novel Therapeutics. Basel: Karger, 2004: 92–109.
10.1159/000079009 Google Scholar
- 34 Sagen JV, Odili S, Bjørkhaug L et al. From clinicogenetic studies of maturity-onset diabetes of the young to unraveling complex mechanisms of glucokinase regulation. Diabetes 2006: 55: 1713–1722.
- 35
Velho G,
Froguel P,
Gloyn A,
Hattersley AT.
Glucokinase and the regulation of blood glucose. In: F Matschinsky,
MA Magnuson, eds. Glucokinase and Glycemic Disease. From Basics to Novel Therapeutics: Basel: Karger, 2004: 42–64.
10.1159/000079006 Google Scholar
- 36 Guenat E, Seematter G, Philippe J, Temler E, Jequier E, Tappy L. Counterregulatory responses to hypoglycemia in patients with glucokinase gene mutations. Diabetes Metab 2000: 26: 377–384.
- 37 Schnyder S, Mullis PE, Ellard S, Hattersley AT, Fluck CE. Genetic testing for glucokinase mutations in clinically selected patients with MODY: a worthwhile investment. Swiss Med Wkly 2005: 135: 352–356.
- 38 Codner E, Deng L, Perez-Bravo F et al. Glucokinase mutations in young children with hyperglycemia. Diabetes Metab Res Rev 2006: 22: 348–355.
- 39 Thomson KL, Gloyn AL, Colclough K et al. Identification of 21 novel glucokinase (GCK) mutations in UK and European Caucasians with maturity-onset diabetes of the young (MODY). Hum Mutat 2003: 22: 417.
- 40 Mantovani V, Salardi S, Cerreta V et al. Identification of eight novel glucokinase mutations in Italian children with maturity-onset diabetes of the young. Hum Mutat 2003: 22: 338.